Brentuximab Vedotin for Newly Diagnosed High-Risk cHL

EFS, where events include disease progression or relapse, second malignancy, or death [ Time Frame: Up to 48 months ] [ Designated as safety issue: No ] Primary analysis will be based 1-sided log rank test comparison of EFS curves between the 2 randomized arms per intention-to-treat principle.

January 19, 2016